Comments
Glenmark Pharmaceuticals Europe Ltd has launched a generic version of Seretide Accuhaler, used to treat asthma, in Denmark. The product was developed by Celon Pharma and Glenmark has the marketing and distribution rights for the product across 15 European countries.
“This is Glenmark’s first inhaled respiratory product launch in Europe. Glenmark is the first generic company to receive regulatory approval for substitution in Denmark for its generic of Seretide Accuhaler,” Glenmark Pharmaceuticals Ltd said in a BSE filing today.
Glenmark had entered into a strategic development and licensing agreement with Celon Pharma S.A. to develop and market a generic version of GlaxoSmithKline’s Seretide Accuhaler product - Fluticasone/Salmeterol dry powder inhaler in 15 European countries.
Fluticasone/Salmeterol dry powder inhaler is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Glenmark said it has already received national marketing authorisations for the product in Sweden, Finland, Norway and Iceland.
Quotng IQVIA data, Glenmark Pharma said Fluticasone/Salmeterol dry powder inhaler had posted sales of $864 million in Europe in the 12-month period ended September 2017. Shares of Glenmark Pharma were trading up by 1.58 per cent at Rs 514.25 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.